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Type 1 nephronophthisis (NPHP) with homozygous deletions
of nephrocystin [NPHP1, DEL] has been considered a pure
renal disorder, but co-occurrence of extrarenal symptoms,
mainly retinitis pigmentosa, is observed in a subset of patients.
Recently, [NPHP1, DEL] has been detected in three patients
with Joubert syndrome-related disorders (JSRDs), who
associated neurological signs with a peculiar neuroradiological
malformation known as the ‘molar tooth sign’ (MTS). To define
the frequency of JSRD spectrum in NPHP1 patients, we
re-examined 56 cases with [NPHP1, DEL] and found an overall
incidence of 8.9% (five out 56 patients). All had small
hyperechoic kidneys and had developed advanced renal
failure within 15 years. Two patients presented the complete
features of JSRD with cerebello-renal-retinal association and
MTS. Two others showed, instead, severe intentional tremor
and thick superior cerebellar peduncles on brain magnetic
resonance imaging (MRI), and one of them had associated
retinopathy. The fifth patient presented with hypotonia,
developmental delay, central deafness, and ataxia associated
with Leber congenital amaurosis and liver fibrosis but with
normal brain MRI. Marked intrafamilial variability of associated
extrarenal symptoms was observed in familial cases. Deletion
extension did not differ in patients with isolated renal
phenotype and in those with associated neurological
symptoms. In conclusion, neurological defects varying from
subtle involvement of cerebellum with thickened peduncle to
both JSRD and diffuse central hypotonia are frequent in [NPHP1,
DEL] patients. Prevalence of such association may justify
systematic neurological and neuroradiological evaluation.
Kidney International (2006) 70, 1342–1347. doi:10.1038/sj.ki.5001768;
published online 9 August 2006
KEYWORDS: pediatric nephrology; kidney disease; genetic renal disease
Nephronophthisis (NPHP) is an autosomal-recessive renal
disorder with onset in infancy or childhood, representing the
most frequent genetic cause of end-stage renal failure (ESRF)
in children. NPHP is clinically heterogeneous, with a subset
of patients presenting associated extrarenal defects. Six
causative genes have been now identified (NPHP1–6).1–7
Homozygous deletions of the NPHP1 gene at 2q13 [NPHP1,
DEL] are responsible for about 40% of cases8–10 and usually
give rise to a pure renal phenotype. However, association with
pigmentary retinopathy (Senior–Loken syndrome) or oculo-
motor apraxia has been reported in NPHP1 patients.11,12
Recently, [NPHP1, DEL] was identified in three patients
with Joubert syndrome-related disorders (JSRDs), a group
of syndromes showing the typical neurological signs
of Joubert syndrome (hypotonia, ataxia, psychomotor
delay, and oculomotor apraxia-type Cogan) and variable
involvement of other organs such as the eye and kidneys.13,14
All JSRDs share a pathognomonic malformation of the
midbrain–hindbrain junction known as the ‘molar tooth
sign’ (MTS), consisting of cerebellar vermis hypo/aplasia,
thick and mal-oriented superior cerebellar peduncles,
and abnormally deep interpeduncular fossa.15 JSRDs are
genetically heterogeneous, with two genes (JBTS3 – AHI1
at 6q23.3 and JBTS5 – CEP290 at 12q21.32) and two
additional loci (JBTS1 at 9q34.3 and JBTS2 at 11p11.2–q12.3)
identified so far.16 Mutations in the AHI1 gene are
occasionally responsible for JSRDs with renal/retinal involve-
ment; at this time, only three families with affected sibling
and NPHP are described.17,18 Recently, a second gene for
Joubert syndrome (CEP290) was identified by two indepen-
dent groups6,7 in a series of families presenting both
neurological and renal symptoms. These observations suggest
overlapping phenotypes to those described in NPHP1-
deleted patients.
To evaluate the frequency and clinical spectrum of neuro-
logical signs associated with NPHP1, we have re-evaluated
56 patients with [NPHP1, DEL] and performed detailed
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clinical and neuroradiological examination in those with
possible neurological involvement.
RESULTS
Among the 125 patients with NPHP, 56 patients presented
[NPHP1, DEL] and four cases carried NPHP1 mutations. This
study focuses on the wide clinical aspects of only the subset of
patients with [NPHP1, DEL]. The remaining 65 patients
without NPHP1 deletion/mutation and the four patients
presenting NPHP1 mutations19 had no signs of neurological
involvement and were not included in the study cohort. All
patients with [NPHP1, DEL] presented typical renal symp-
toms, including polyuria, polydipsia, low urine osmolality, and
small kidneys without corticomedullary differentiation and
occasional cysts. Creatinine levels were variable and indepen-
dent from age, whereas renal failure was a constant finding.
Five patients (8.9%) had signs of neurological involve-
ment, and underwent detailed neurological and ophthalmo-
logic examination and brain magnetic resonance imaging
(MRI). Clinical features of these five subjects are presented in
Table 1. Three patients had at least another sibling with
[NPHP1, DEL] (Fam.2, ZR; Fam.3, CM; and Fam.4, PC),
whereas two cases (Fam.1, PL and Fam.5, LF) were sporadic.
In familial cases, neurological and ophthalmologic assess-
ment was extended to the available affected siblings even in
the absence of obvious neurological symptoms.
Joubert syndrome-related disorders
Two patients from two different families (Fam.1, PL and
Fam.2, ZR) received a diagnosis of JSRD based on the
neuroradiological finding of the MTS (Figure 1).
Patient 1 (Fam.1, P.L) is a 12-year-old boy who developed
ESRF and required peritoneal dialysis at the age of 11 years.
Oculomotor apraxia, horizontal nystagmus, ataxia with
severe walking difficulties, and moderate tremor had been
present for years, but had not been further investigated until
the present study. No retinal symptoms were present. Brain
MRI demonstrated a mild MTS with moderate inferior
vermis hypoplasia, narrowing of the isthmus, and superior
cerebellar peduncles that were maloriented but not thickened
(Figure 1).
Patient 2 (Fam.2, ZR) had developed ESRF at the age of
15 years. He had a renal transplant at the age of 20 years and
died of infectious complications at 31 years. Clinical records
reported early psychomotor delay and hypotonia. Fundus
oculi examination had demonstrated retinitis pigmentosa
and electroretinogram was abnormal.11 A brain MRI,
performed at the age of 17 years, showed the MTS with
vermis hypoplasia, narrowing of the isthmus, and elongation
of superior cerebellar peduncles (Figure 1). Two siblings
of the proband carried the [NPHP1, DEL]. His sister, aged
41 years (Fam.2 ZS), developed ESRF at 17 years, which
required hemodialysis and renal transplant. She denied any
Table 1 | Clinical details of the five families with homozygous NPHP1 deletion associated with neurological defects
Fam.1 Fam.2 Fam.3 Fam.4 Fam.5
Patient (sex) PL (M) ZR (M) ZS (F) CC (M) CM (M) CD (M) PC (M) PE (F) LF (M)
Age (years) 11 31 41 21 18 14 36 32 15
Kidneys
Polyuria/polydipsia + + + + ++ ++ + + +
Urine osm (mOsm/l) o250 o250 o250 o250 o250 o250 o250 o250 o250
Creatinine (mg%)    1,30 5 4   2
End-stage renal failure PD HD/TX HD/TX    HD/TX HD/TX 
Central nervous system
Psychomotor delay + +       
Intentional tremor + +   ++ + ++  +
Ataxia + +       +
Hypotonia + +       +
Oculomotor apraxia + +       
Nystagmus + +       +
Brain MRI
Molar tooth sign + + ND     ND 
Thick superior cerebellar peduncles   ND  +  + ND 
Eyes
LCA/retinitis pigmentosa  + +    +  +
Flat electroretinogram ND + ND    +  +
Liver
Elevated enzymes         +
Abnormal ultrasound         +
Other signs         Deafness
HD, hemodialysis; LCA, Leber congenital amaurosis; MRI, magnetic resonance imaging; ND, not determined; NPHP, nephronophthisis; PD, peritoneal dialysis; TX, renal
transplant.
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neurological symptoms and refused to undergo further
diagnostic assessment. The proband’s brother died of renal
failure at 10 years; no further clinical details are available.
Intentional tremor and thick superior cerebellar peduncles
The association of intense intentional tremor with thickened
superior cerebellar peduncles on brain MRI (in the absence of
a clear MTS) was observed in two patients from two distinct
families (Figure 2; Fam.3, CM and Fam.4, PC).
Family 3 comprises three male patients of 14, 18, and
21 years who carry the [NPHP1, DEL]. The two younger
brothers had ESRF with creatinine serum levels of 4 and
5 mg%, respectively, whereas creatinine was only slightly
elevated (1.3 mg%) in the oldest brother. The proband
presented from the age of 10 years an intense action and
postural tremor upon extending arms and/or performing
common tasks such as writing or eating, which severely
impaired daily life activities. Video polygraphy was altered
according to clinical symptoms, whereas retinal examination
was unremarkable. A brain MRI, performed at the age of
17 years, showed normal cerebellar vermis but thickening of
superior cerebellar peduncles (Figure 2; Fam.3, CM). The
proband’s younger brother (Fam.3, CD) had mild intentional
arm tremor, whereas the elder brother (Fam3, CC) was
neurologically normal. Both sibling had a normal brain MRI
scan.
Patient 4 is a 36-year-old man who developed ESRF at the
age of 10 years (Figure 2; Fam.4, PC). He received two renal
grafts: the first was lost for acute rejection, whereas the
second was still functioning after 3 years. He reported intense
intentional arm tremor from the age of 5 years with severe
impairment of most daily living activities. Video polygraphy
was markedly altered. The legs were not affected and he could
walk normally. Brain MRI showed normal cerebellar vermis
and thickened superior cerebellar peduncles (Figure 1; case
4). The patient who reported nocturnal visual impairment
and visual assessment at the age of 15 years showed a flat
electroretinogram. The proband’s sister (Figure 2; Fam.4,
PE), aged 32 years, also carries [NPHP1, DEL] and developed
ESRF at 13 years. Her neurological and ophthalmologic
examination were normal and she refused to undergo brain
MRI.
n.a
Fam.1 Fam.2
PL ZR
Figure 1 | MRI in two patients with [NPHP1, DEL] and JSRD. A
typical MTS is evident in both cases at axial sections. MRI paramedian
sagittal section was available in only one child.
CC CM CD PC
Fam.3 Fam.4
Figure 2 | MRI in three patients with [NPHP1, DEL] and intense tremor who did not present MTS. Axial sections demonstrated
thickening of cerebellar peduncles (arrows) in two out of three children (CM in Fam.3 and PC in Fam.4). CD in Fam.3 presented tremor but
was normal at MRI. The last sib in Fam.3 (CC) was [NPHP1, DEL] had no evidence of neurological involvements.
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Psychomotor delay, hypotonia, and central deafness
Patient 5 (Fam.5, LF), aged 15 years, presented mild
developmental delay, hypotonia, and reduced hearing func-
tion from birth. Visual loss was evident at the age of 2 years
and the patient became blind by the age of 10 years.
Ophthalmologic examination showed patchy retinal deposits
of pigments and a flat electroretinogram, whereas audio-
metry- and acoustic-evoked potentials demonstrated central
hearing loss. On latest examination, he presented mild
hypotonia and fine tremor of fingers upon arm extension,
with no other neurological abnormalities and without mental
retardation. Brain MRI was unremarkable. Liver enzymes
were constantly elevated and an abdominal ultrasound
showed liver hyperechogenicity, suggesting hepatic fibrosis.
A sister of 9 years is healthy.
Molecular studies
The extension of the deleted region was evaluated in all
[NPHP1, DEL] patients according to the scheme described in
Materials and Methods. Fifty-four patients (including
patients with JSRD) carried the classical B250 kb homo-
zygous deletion from exon 2 of LOC205251 to 9657T
markers, located in intron 1 of MALL. Two patients with a
pure renal form of NPHP1 carried ‘instead’ a shorter
(B180 kb) deletion spanning from 804/6 to 9657T (Table 2).
DISCUSSION
Neurological symptoms can be part of the clinical spectrum
of [NPHP1, DEL], but a real estimate of their frequency is
not available.20 We could document five out of 56 NPHP1
patients (8.9%) presenting neurological signs that varied
from JSRD and MTS to isolate severe tremor and with
thickening of superior cerebellar peduncles. A more complex
phenotype with hypotonia, developmental delay, ataxia, and
central deafness was also found in one child. Overall,
neurological defects in NPHP1 seem phenotypically wider
than previously reported,16 and are, at the same time, more
frequent than assumed. A major issue is the variability of
clinical presentation. The two patients described here
confirm the previously reported association between
[NPHP1, DEL] and JSDR/MTS and extend to five times
the number of cases reported in the literature. Interestingly,
all of these cases (including the two cases reported here)
presented a ‘milder’ form of JSDR, with moderate cerebellar
vermis hypoplasia and elongation, but not thickening of
superior cerebellar peduncles that seems to be a peculiar
aspect of the association.13,14 Therefore, a careful evaluation
of brain MRIs, even in the absence of clear neurological
involvement, such as in the case of simple arm tremor, is
crucial for a correct clinical diagnosis. Moreover, molecular
diagnostic testing in JSRD patients with renal involvement
and NPHP1 deletion should always be investigated when
such distinctive form of MTS is observed on brain MRI.
The description of patients with intense tremor and
thickened superior cerebellar peduncles in the absence of a
clear MTS has never been reported so far and expands the
clinical presentation of [NPHP1, DEL] patients. This
phenotype is easily recognizable on clinical examination
and could be part of the same clinical spectrum as JSRD. In
fact, thickening of superior cerebellar peduncles could repre-
sent an even milder form of MTS, without obvious cerebellar
vermis hypoplasia. However, this requires confirmation in
additional cases.
A single patient with [NPHP1, DEL] presented a complex
syndrome consisting of hypotonia, ataxia, central hearing
loss, and Leber congenital amaurosis associated with possible
liver fibrosis. Leber congenital amaurosis and liver fibrosis are
also part of the phenotypic spectrum of JSRD and central
hearing loss has been occasionally reported as an associated
feature, but brain imaging was surprisingly normal in the
patient reported here. We cannot exclude that this patient
could be affected by a yet undefined disorder that may be
associated to [NPHP1, DEL] purely by chance.
Overall, we have observed different neurological pheno-
types associated with the same underlying molecular defect,
that is, [NPHP1, DEL]. On the other hand, it is now evident
that renal symptoms from alteration of urine concentrating
potential to overt renal failure are frequent in patients with
JSRD without [NPHP1, DEL] (manuscript in preparation),
and therefore there is an overlap between JSRD with renal
involvement (25%) and type 1 NPHP with MTS and/or
tremor (9%). Recent papers confirm the association between
Table 2 | List of molecular STS markers utilized for testing the
presence of NPHP1 deletion
Genes Amplimers bp References A B
LOC205251 Exon 1 79 UCSC*
del16F 102 31
Exon 2 128 UCSC*
Exon 6 131 UCSC*
del2F 123 31
Exon 7 175 UCSC*
Exon 9 95 UCSC*
NPHP1 Exon 1 60 1
804/6 215 8
Exon 3 61 1
107O20S 199 10
Exon 9 88 1
146c2T-2 158 10
Exon 10 95 1
765F2L 142 8
del-5 185 31
Exon 20 191 1
MALL del10F 213 31
Exon 1 100 1
9657T-1 172 10
del9F 93 31
Exon 2 168 1
del18F 112 31
Exon 3 126 1
Exon 4 804 1
del4F 182 31
57N19S-1 97 10
6E19S-1 94 10
Columns A (classical deletion) and B (short deletion) represent in
dark the homozygous-deleted markers. Gray markers indicated duplicated regions.
Non-exonic markers are in bold. The UCSC Genome Browser (http://genome.ucsc.
edu) was utilized for searching these markers (*).
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NPHP and Joubert syndrome. Utsch et al.17 identified the
first NPHP and associated Joubert syndrome patient with
AHI1 mutations. Two independent groups identified a new
gene responsible for both nephrophthisis and Joubert
syndrome; it encodes a large centrosomal protein named
CEP290 that is involved in the control of ciliary activity.6,7
Such ‘splitting and lumping’ raises a basic molecular
question related to the pathogenesis of [NPHP1, DEL]
overlapping syndromes. Although no definite answer is
available at present, functional studies on the interaction
between NPHP1-encoded nephrocystin and proteins in-
volved in JSRDs such as Jouberin (encoded by the AHI1
gene) and CEP290 should be carried out to explain the
clinical continuum between the above situations. Interest-
ingly, nephrocystin and Jouberin share some structural
homologies including an SH3 domain and several SH3
binding sites for protein–protein interaction, which are
typical of proteins involved in signal transduction and
cytoskeleton assembly. Louie and Glesson15 recently pro-
posed a model for cilia-based signalling in cerebellar
development and potential role of Jouberin and nephro-
cystin. Although this possibility still requires experimental
evidence, cilia have been recognized as crucial organelles
present in distinct types of neurons as well as in renal tubule
epithelial cells and are currently considered a basic mechan-
ism for cyst transformation at this site (for a review see
Menezes et al.21). The wide concept about an implication of
ciliar proteins in cyst degeneration of the kidney is not
confined to all identified NPHP genes, but may be extended
to other renal cyst diseases such as dominant and recessive
polycystic kidney disease,22 Bardet–Biedl genes,23 and Oro–
Facial–Digital syndrome.24 Therefore, most of the renal
diseases characterized by cysts are owing to mutations
of genes coding for ciliary or centrosomal proteins that
points to an unexpected convergence of mechanisms. In fact,
many cysto proteins present coiled-coil domains and
participate in protein-to-protein complexes. The basic
mechanism of cilia implication in cyst transformation is
not clear and few possibilities may be hypothesized.25 The
first is related to the mechanosensory function of cilia that is
mainly supported by animal models of specific kidney gene
inactivation.21 Other implications of centrosomes and
cystoproteins in cell cycle regulation and/or modulation of
transcriptional pathways such as Wnt and AP1 may play
additive functions.26
A second important question relates to the marked
intrafamilial variability evident in our series. We excluded
that such variability is owing to a different extension of the
2q13 deletion and alternative possibilities must be consid-
ered. An oligogenic model of disease transmission, in which
multiple loci exert a synergistic effect to modify the
expressivity of the disease trait, should be considered.27
Bardet–Biedl syndrome, another autosomal-recessive disease,
represents a very nice example of this.28 Eleven genes have
been identified,29 and in some patients, three mutations
across two Bardet–Biedl syndrome loci interact to modify the
onset and the severity of phenotype.30 This situation may
explain the phenotypic variability observed in our patients.
In conclusion, neurological defects varying from subtle
cerebellar involvement to clear JSRD phenotypes are not so
rare as expected in [NPHP1, DEL] patients and can be
occasionally associated with retinal defects. The prevalence of
such association justifies neurological and neuroradiological
approaches in selected [NPHP1, DEL] patients.
MATERIALS AND METHODS
Patients
One hundred and twenty-five consecutive patients with intense
polyuria and polydipsia were ascertained at the Nephrology Unit of
G Gaslini Children Hospital over 10 years (1995–2004). For all
patients, the diagnostic approach included clinical tests, ultrasound
of kidneys and liver, and molecular tests to detect NPHP1 deletion
and/or mutations. Fifty-six patients (44.8%) presented [NPHP1,
DEL], whereas four patients were mutated (three with heterozygous
NPHP1 deletion plus point NPHP1 mutation; one with NPHP1
compound heterozygous mutation).19 At the time of diagnosis, all
these patients showed clinical and laboratory signs of NPHP,
including urinary concentration defect (failure to increase fresh
urine osmolality over 400 mOsm after desmopressin stimulation),
increase of serum creatinine levels above the normal range for age,
and small hyperechoic kidneys without corticomedullary differ-
entiation. More than 50% patients had already developed ESRF and
almost all with ESRF had been transplanted. Patients with possible
neurological involvement underwent detailed neurological and
ophthalmologic examination and instrumental testing, including
brain MRI, EEG, graphology, evaluation of fundus oculi, and
electroretinogram.
Molecular genetics
Written informed consent for genetic studies was obtained from
each patient or the legal tutor in the case of minors. NPHP1
homozygous deletion was tested by evaluating STS markers 804/6
and 9657T, mapping within NPHP1 intron 1 and MALL intron 1,
respectively.8–10,31 To evaluate the extension of the deletion 30 of
NPHP1 gene, new STS markers were generated within the
LOC205251 gene by UCSC human genome database inspection
and are listed in Table 2. Flanking regions between 9657T (located in
MALL intron 1) and LOC205251 exon2 were not considered
informative owing to the presence of segmental duplications and
direct-inverted repeats. In all polymerase chain reaction experi-
ments, an STS marker, external to the homozygous-deleted region,
were co-amplified in order to test the presence of DNA sample.
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